MARKET

KYMR

KYMR

Kymera Therapeutics, Inc.
NASDAQ
79.47
+1.31
+1.68%
Opening 11:56 03/30 EDT
OPEN
78.73
PREV CLOSE
78.16
HIGH
80.74
LOW
77.47
VOLUME
107.42K
TURNOVER
--
52 WEEK HIGH
103.00
52 WEEK LOW
19.45
MARKET CAP
6.49B
P/E (TTM)
-21.5658
1D
5D
1M
3M
1Y
5Y
1D
Kymera Therapeutics presents results from BroADen Phase 1b AD trial of KT-621
TipRanks · 1d ago
Kymera says oral STAT6 degrader KT-621 shows positive Phase 1b atopic dermatitis data
Reuters · 2d ago
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Barchart · 2d ago
Kymera Therapeutics Updates Bylaws on Federal Securities Litigation
TipRanks · 2d ago
Kymera Therapeutics amends bylaws; federal district courts named exclusive forum for Securities Act and Exchange Act claims
Reuters · 2d ago
Kymera Therapeutics; COO Jeremy G Chadwick disposes of common shares worth $9,033,226
Reuters · 4d ago
Weekly Report: what happened at KYMR last week (0316-0320)?
Weekly Report · 03/23 09:55
Kymera Therapeutics director Pamela Esposito disposes of USD 198,920 in common shares
Reuters · 03/20 22:30
More
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.

Webull offers Kymera Therapeutics Inc stock information, including NASDAQ: KYMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYMR stock methods without spending real money on the virtual paper trading platform.